HomeAI · summaries
Storia in 4 fonti
Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
Moderna plans a $2B convertible note offering; AstraZeneca-Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits China gene therapy deal; Gates Foundation backs ProFound on preeclampsia.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
qz.com
Moderna raises $2 billion in convertible notes for cancer vaccine
The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a multi-year high
- ·
benzinga.com
Moderna Borrows $2 Billion To Expand Oncology Business - Moderna (NASDAQ:MRNA)
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.
